137 related articles for article (PubMed ID: 36413741)
1. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy.
Dzimitrowicz HE; Wilson LE; Jackson BE; Spees LP; Baggett CD; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Leapman MS; Gross CP; Dinan MA; Wheeler SB
JCO Oncol Pract; 2023 Feb; 19(2):e213-e227. PubMed ID: 36413741
[TBL] [Abstract][Full Text] [Related]
2. Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.
Kaye DR; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Pollack CE; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB; Dinan MA
J Geriatr Oncol; 2022 Jun; 13(5):614-623. PubMed ID: 35125336
[TBL] [Abstract][Full Text] [Related]
3. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC).
Dinan MA; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Kaye D; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB
Urology; 2022 Oct; 168():129-136. PubMed ID: 35878815
[TBL] [Abstract][Full Text] [Related]
4. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.
Pritchard JE; Wilson LE; Miller SM; Greiner MA; Cohen HJ; Kaye DR; Zhang T; Dinan MA
J Am Geriatr Soc; 2022 Aug; 70(8):2330-2343. PubMed ID: 35499667
[TBL] [Abstract][Full Text] [Related]
5. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
Spees LP; Wheeler SB; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Leapman M; Gross CP; Dinan MA
Cancer Med; 2021 Oct; 10(19):6653-6665. PubMed ID: 34480518
[TBL] [Abstract][Full Text] [Related]
6. Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.
Spees LP; Dinan MA; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George DJ; Scales CD; Pritchard JE; Leapman M; Gross CP; Wheeler SB
Clin Genitourin Cancer; 2022 Oct; 20(5):e396-e405. PubMed ID: 35595633
[TBL] [Abstract][Full Text] [Related]
7. Aggressive end-of-life care across gradients of cognitive impairment in nursing home patients with metastatic cancer.
Koroukian SM; Douglas SL; Vu L; Fein HL; Gairola R; Warner DF; Schiltz NK; Cullen J; Owusu C; Sajatovic M; Rose J
J Am Geriatr Soc; 2023 Nov; 71(11):3546-3553. PubMed ID: 37515440
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Aggressive End-of-Life Care Among Older Adults With Metastatic Cancer Living in Nursing Homes and Community Settings.
Koroukian SM; Douglas SL; Vu L; Fein HL; Gairola R; Warner DF; Schiltz NK; Cullen J; Owusu C; Sajatovic M; Rose J
JAMA Netw Open; 2023 Feb; 6(2):e230394. PubMed ID: 36811860
[TBL] [Abstract][Full Text] [Related]
9. Associations Between Health Literacy and End-of-Life Care Intensity Among Medicare Beneficiaries.
Luo Q; Shi K; Hung P; Wang SY
Am J Hosp Palliat Care; 2021 Jun; 38(6):626-633. PubMed ID: 33472379
[TBL] [Abstract][Full Text] [Related]
10. Comparing the use of aggressive end-of life care among frail and non-frail patients with cancer using a claims-based frailty index.
Sachdev R; Shearn-Nance G; Vu L; Bensken WP; Douglas SL; Koroukian SM; Rose J
J Geriatr Oncol; 2024 Mar; 15(2):101706. PubMed ID: 38320468
[TBL] [Abstract][Full Text] [Related]
11. End-of-life care quality outcomes among Medicare beneficiaries with hematologic malignancies.
Egan PC; LeBlanc TW; Olszewski AJ
Blood Adv; 2020 Aug; 4(15):3606-3614. PubMed ID: 32766855
[TBL] [Abstract][Full Text] [Related]
12. Association of Advance Care Planning Visits With Intensity of Health Care for Medicare Beneficiaries With Serious Illness at the End of Life.
Weissman JS; Reich AJ; Prigerson HG; Gazarian P; Tjia J; Kim D; Rodgers P; Manful A
JAMA Health Forum; 2021 Jul; 2(7):e211829. PubMed ID: 35977213
[TBL] [Abstract][Full Text] [Related]
13. Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.
Wheeler SB; Spees LP; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Dinan MA
JCO Oncol Pract; 2021 Dec; 17(12):e1895-e1904. PubMed ID: 34138665
[TBL] [Abstract][Full Text] [Related]
14. Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States.
Wilson LE; Spees L; Pritchard J; Greiner MA; Scales CD; Baggett CD; Kaye D; George DJ; Zhang T; Wheeler SB; Dinan MA
Kidney Cancer; 2021; 5(3):115-127. PubMed ID: 34632169
[TBL] [Abstract][Full Text] [Related]
15. Role of Home Health for Community-Dwelling Older Adults Near the End of Life: A Resource Beyond Hospice?
Oh A; Hunt LJ; Ritchie CS; Ornstein KA; Kelley AS; Rajagopalan S; Ankuda CK
J Palliat Med; 2023 Mar; 26(3):385-392. PubMed ID: 36137095
[No Abstract] [Full Text] [Related]
16. Predictors of high-intensity care at the end of life among older adults with solid tumors: A population-based study.
Baird CE; Wulff-Burchfield E; Egan PC; Hugar LA; Vyas A; Trikalinos NA; Liu MA; Bélanger E; Olszewski AJ; Bantis LE; Panagiotou OA
J Geriatr Oncol; 2024 Jun; 15(5):101774. PubMed ID: 38676975
[TBL] [Abstract][Full Text] [Related]
17. Association of Billed Advance Care Planning with End-of-Life Care Intensity for 2017 Medicare Decedents.
Gupta A; Jin G; Reich A; Prigerson HG; Ladin K; Kim D; Ashana DC; Cooper Z; Halpern SD; Weissman JS
J Am Geriatr Soc; 2020 Sep; 68(9):1947-1953. PubMed ID: 32853429
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Contribution of Patient-Provider Communication and Cancer Diagnosis to Racial Disparities in End-of-Life Care Among Medicare Beneficiaries.
Samuel-Ryals CA; Mbah OM; Hinton SP; Cross SH; Reeve BB; Dusetzina SB
J Gen Intern Med; 2021 Nov; 36(11):3311-3320. PubMed ID: 33963508
[TBL] [Abstract][Full Text] [Related]
19. Association between survival time with metastatic breast cancer and aggressive end-of-life care.
Accordino MK; Wright JD; Vasan S; Neugut AI; Gross T; Hillyer GC; Hershman DL
Breast Cancer Res Treat; 2017 Nov; 166(2):549-558. PubMed ID: 28752188
[TBL] [Abstract][Full Text] [Related]
20. End-of-life quality metrics among medicare decedents at minority-serving cancer centers: A retrospective study.
Wasp GT; Alam SS; Brooks GA; Khayal IS; Kapadia NS; Carmichael DQ; Austin AM; Barnato AE
Cancer Med; 2020 Mar; 9(5):1911-1921. PubMed ID: 31925998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
